Typhoid Vi Polysaccharide Vaccine Market Size, Insights, Analysis Report 2024-2033

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Typhoid Vi Polysaccharide Vaccine Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $11.28 billion In 2028 At A CAGR Of 17.9% :

The typhoid vi polysaccharide vaccine market size has grown rapidly in recent years. It will grow from $4.98 billion in 2023 to $5.84 billion in 2024 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to disease prevalence, global health initiatives, traveler vaccination, government immunization efforts, vaccine efficacy and safety.

The typhoid vi polysaccharide vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.28 billion in 2028 at a compound annual growth rate (CAGR) of 17.9%. The growth in the forecast period can be attributed to expanded immunization programs, global health policy focus, epidemiological surveillance, rising demand in travel medicine, environmental and social factors. Major trends in the forecast period include r&d investments, regulatory support, epidemiological studies, public health awareness.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Typhoid Vi Polysaccharide Vaccine Market Major Segments
The typhoid vi polysaccharide vaccine market covered in this report is segmented -

1) By Type: Child, Adult
2) By Route of Administration: Oral, Parenteral
3) By Application: Government Institution, Private Sector, Other Applications

Key Driver - Escalating Typhoid Prevalence Fuels Expansion In The Typhoid Vi Polysaccharide Vaccine Market

Rising typhoid prevalence is expected to propel the growth of the typhoid VI polysaccharide vaccine market going forward. Typhoid is an infection caused by the bacteria Salmonella typhi that can be fatal. It usually spreads through contaminated food or drink. Typhoid Vi polysaccharide vaccine is used to immunise adults and children aged 2 and up against typhoid fever caused by Salmonella enterica serovar Typhi, S. Typhi. For instance, in March 2021, according to a report shared by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, infections with Salmonella Typhi were believed to affect 5,700 Americans annually, with 620 of these likely to require hospitalization. Typhoid fever mostly causes between 11 and 21 million cases worldwide every year, along with 200,000 fatalities. Therefore, the rising typhoid prevalence is driving the growth of the typhoid Vi polysaccharide vaccine market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=8313&type=smp

Prominent Trend - International Vaccine Institute's Dynamic Partnerships With Moderna And Gsk Fuel Advances In Typhoid Vi Polysaccharide Vaccine Market

Strategic partnerships are a key trend gaining popularity in the typhoid Vi polysaccharide vaccine market. Major companies operating in the typhoid Vi polysaccharide vaccine market are entering into partnerships to strengthen their position in the typhoid Vi polysaccharide market. For instance, in July 2022, The International Vaccine Institute, a South Korea-based international organization focused on infectious diseases of global health importance such as cholera, typhoid, shigella, and salmonella, partnered with Moderna, a US-based biopharmaceutical company. This partnership led to the world's first affordable oral cholera vaccine and a new-generation typhoid conjugate vaccine.

Typhoid Vi Polysaccharide Vaccine Market Players
Major companies operating in the typhoid vi polysaccharide vaccine market report are Sanofi Pasteur SA, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer Inc., Johnson & Johnson Private Limited, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Emergent Biosolutions Inc., PT Bio Farma, Bharat Biotech International Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, Mylan NV, Serum Institute of India Pvt. Ltd., Biological E. Limited, Panacea Biotec Ltd., Shantha Biotechnics Pvt. Ltd., Cadila Healthcare Ltd., Merck Sharp & Dohme Corp., AstraZeneca Limited, Boryung Pharmaceutical Co., Bio-Med Pvt. Ltd., LG Chem, SK Chemicals Co. Ltd., Crucell Switzerland AG, Hualan Biological Engineering Inc., Indian Immunologicals Limited

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Largest And Fastest Growing Region In The Market
Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2023. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Typhoid Vi Polysaccharide Vaccine Market Report Structure
3. Typhoid Vi Polysaccharide Vaccine Market Trends And Strategies
4. Typhoid Vi Polysaccharide Vaccine Market - Macro Economic Scenario
5. Typhoid Vi Polysaccharide Vaccine Market Size And Growth
…..
27. Typhoid Vi Polysaccharide Vaccine Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.